25 recruiting. 25 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 25 | Recruiting 25 |
| Phase 2 | 3 | Recruiting 3 |
Follow Glomerulonephritis: new trials by email Literature Review of Glomerulonephritis trials Research Report on Glomerulonephritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy Inebilizumab, Tacrolimus - Glomerulonephritis, Membranous | Phase 3 | Recruiting | Amgen | 159 | 2026-10-01 | 2026-10-01 |
| Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN Drug: Atrasentan - Berger Disease, Bergers Disease | Phase 3 | Recruiting | Novartis Pharmaceuticals | 28 | 2026-08-06 | 2026-10-15 |
| Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN HSK39297, Placebo - IgA Nephropathy (IgAN) | Phase 3 | Recruiting | Haisco Pharmaceutical Group Co., Ltd. | 370 | 2026-04-07 | 2026-05-28 |
| A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS) BI 764198, Placebo - Focal Segmental Glomerulosclerosis | Phase 3 | Recruiting | Boehringer Ingelheim | 286 | 2026-02-16 | 2026-10-28 |
| A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment Cenerimod, Placebo - Nephritis, Lupus, Lupus Erythematosus, Systemic | Phase 3 | Recruiting | Viatris Innovation GmbH | 300 | 2026-02-09 | 2026-07-30 |
| Combination of Rituximab and Cyclosporine in the Treatment of Primary Membranous Nephropathy Rituximab combined with cyclosporine, rituximab - Membranous Nephropathy | Phase 2 / Phase 3 | Recruiting | Peking University First Hospital | 90 | 2026-01-21 | 2026-10-06 |
| Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN iptacopan - Primary Immunoglobulin A Nephropathy (IgAN) | Phase 3 | Recruiting | Novartis Pharmaceuticals | 31 | 2025-11-27 | 2026-09-09 |
| A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis BAT4406F, Placebos - Minimal Change Disease (MCD), Focal Segmental Glomerulosclerosis (FSGS) | Phase 2 / Phase 3 | Recruiting | Bio-Thera Solutions | 192 | 2025-10-26 | 2026-04-03 |
| Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study Obinutuzumab administration - Membranous Nephropathy - PLA2R Induced | Phase 2 / Phase 3 | Recruiting | Radboud University Medical Center | 20 | 2025-10-01 | 2026-01-06 |
| Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy. zigakibart - Kidney Diseases, Kidney Diseases, Chronic | Phase 3 | Recruiting | Novartis Pharmaceuticals | 220 | 2025-07-28 | 2026-08-17 |
| Study of Ravulizumab in Pediatric Participants With Primary IgAN Ravulizumab - IgAN, IgAVN | Phase 3 | Recruiting | Alexion Pharmaceuticals, Inc. | 36 | 2025-06-14 | 2026-07-30 |
| A Trial of HRS-5965 Capsule in Primary IgA Nephropathy HRS-5965, Placebo - Primary IgA Nephropathy | Phase 3 | Recruiting | Chengdu Suncadia Medicine Co., Ltd. | 378 | 2025-06-04 | 2025-08-05 |
| Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension) Ianalumab - Lupus Nephritis | Phase 3 | Recruiting | Novartis Pharmaceuticals | 348 | 2025-05-19 | 2026-10-13 |
| A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) Felzartamab, Placebo - Immunoglobulin A Nephropathy (IgAN) | Phase 3 | Recruiting | Biogen | 454 | 2025-05-08 | 2026-10-14 |
| Chimeric Antigen Receptors T Cells for Refractory/Recurrent Lupus Nephritis in Children Low-dose CAR-T cells group, High-dose CAR-T cells group - Lupus Nephritis | Phase 3 | Recruiting | Guangzhou Women and Children's Medical Center | 50 | 2025-05-01 | 2025-04-01 |
| A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria SC0062 strength 10mg, Placebo matched to SC0062 - IgA Nephropathy (IgAN) | Phase 3 | Recruiting | Biocity Biopharmaceutics Co., Ltd. | 360 | 2025-02-14 | 2025-02-17 |
| Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX) RiTUXimab Injection - Membranous Nephropathy | Phase 3 | Recruiting | Centre Hospitalier Universitaire de Nice | 120 | 2025-02-04 | 2026-06-22 |
| Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS Iptcaopan 200 mg - Atypical Hemolytic Uremic Syndrome | Phase 3 | Recruiting | Novartis Pharmaceuticals | 65 | 2024-05-08 | 2026-06-04 |
| Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD Prednisolone, Prednisolone plus Cyclophosphamide - Glomerulonephritis, IGA | Phase 3 | Recruiting | Air Force Military Medical University, China | 208 | 2024-02-01 | 2024-05-06 |
| A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis Voclosporin（QL1074）, Placebo - Lupus Nephritis | Phase 3 | Recruiting | Qilu Pharmaceutical Co., Ltd. | 270 | 2023-12-25 | 2024-05-09 |
Showing 20 of 25. Sign in to see all of them.
Glomerulonephritis, IGA (10) · Glomerulonephritis, Membranous (5) · Lupus Nephritis (5) · Glomerulosclerosis, Focal Segmental (3) · Kidney Diseases (3) · Renal Insufficiency, Chronic (3) · Glomerulonephritis, Membranoproliferative (2) · Lupus Erythematosus, Systemic (2) · Proteinuria (2) · Urologic Diseases (2) · Atypical Hemolytic Uremic Syndrome (1) · Autoimmune Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1)
Female Urogenital Diseases (24) · Female Urogenital Diseases and Pregnancy Complications (24) · Male Urogenital Diseases (24) · Nephritis (24) · Urogenital Diseases (24) · Urologic Diseases (23) · Kidney Diseases (22) · Immune System Diseases (21) · Autoimmune Diseases (19) · Skin and Connective Tissue Diseases (6) · Connective Tissue Diseases (5) · Pathological Conditions, Signs and Symptoms (5) · Pathologic Processes (4) · Chronic Disease (3)
Rituximab (3) · iptacopan (3) · Cyclophosphamide (2) · Prednisone (2) · Acetaminophen (1) · Atrasentan (1) · Cyclosporine (1) · Mycophenolic Acid (1) · Prednisolone (1) · Premedication (1) · Tacrolimus (1) · cenerimod (1) · dexchlorpheniramine (1) · felzartamab (1) · ianalumab (1)
Novartis Pharmaceuticals (7) · Air Force Military Medical University, China (1) · Alexion Pharmaceuticals, Inc. (1) · Amgen (1) · Assistance Publique - Hôpitaux de Paris (1) · Bio-Thera Solutions (1) · Biocity Biopharmaceutics Co., Ltd. (1) · Biogen (1) · Boehringer Ingelheim (1) · Centre Hospitalier Universitaire de Nice (1) · Chengdu Suncadia Medicine Co., Ltd. (1) · Dimerix Bioscience Pty Ltd (1) · Guangzhou Women and Children's Medical Center (1) · Haisco Pharmaceutical Group Co., Ltd. (1) · Peking Union Medical College Hospital (1)
China (19) · United States (12) · France (9) · Japan (9) · Spain (9) · Taiwan (8) · Argentina (7) · Brazil (7) · South Korea (7) · Australia (6) · Czechia (6) · Italy (6) · Malaysia (6) · Turkey (Türkiye) (6) · Canada (5)
Anne-Els Van de Logt, M.D., PhD (1) · David Fuller (1) · Guangyan Cai, MD (1) · Yan Qin (1)
PMID 33693991, PMID 38724717, PMID 40180405, PMID 40465397, PMID 42384439
2025 (3), 2023 (2), 2018 (1)